Your Pain Runs Deep. Your Genes May Be Why.

COMT is an enzyme that breaks down dopamine and norepinephrine, two neurotransmitters central to pain modulation. When these neurotransmitters are available at the right levels, your nervous system is better able to suppress pain signals. Think of COMT as the brakes on your pain-inhibition system; it decides how long these protective neurochemicals linger in your synapses.

The COMT Val158Met variant is one of the most common genetic differences affecting pain sensitivity. Roughly 25% of people of European ancestry are homozygous for the slow variant, meaning they clear these neurotransmitters more slowly. A slow COMT keeps pain-protective neurochemicals in circulation longer, which sounds good, but the reality is more complex: slow COMT carriers often have heightened pain perception, lower pain thresholds, and amplified migraine and fibromyalgia severity. The slow variant may seem protective, but it appears to dysregulate the overall pain-modulation balance.

If you carry a slow COMT variant, you likely notice that caffeine worsens your pain, stress triggers flares, and high-stimulation environments intensify your symptoms. You may feel pain more vividly than others around you, and recovery from injury takes longer. Bright lights, loud noises, and crowded spaces may all amplify your pain perception because your nervous system is processing sensory information with fewer brakes.

OPRM1 encodes the mu-opioid receptor, the key lock that endogenous opioids bind to in order to suppress pain. Your body makes its own opioids, called endorphins and enkephalins. When these bind to mu-opioid receptors, pain signals are dampened. OPRM1 determines how effectively this natural pain-relief system works.

The OPRM1 A118G variant (rs1799971), carried by roughly 10 to 15% of people of European ancestry (and up to 40% in East Asian populations), reduces the receptor’s sensitivity to both endogenous and exogenous opioids. People with the G allele have a naturally lower capacity for opioid-mediated pain relief; their endogenous opioid system is simply less effective at the molecular level. This is not a pain disorder in the psychiatric sense; it’s a pharmacogenetic reality.

If you carry the OPRM1 G allele, you’ve likely noticed that opioid medications (if you’ve taken them) required higher doses to be effective, or that you tolerate pain longer than others before your natural pain-relief system kicks in. You may feel pain more intensely during stress, because stress-induced endorphin release is less impactful for you. Recovery from injury feels slower, and you may have a persistently lower pain threshold compared to family members with the A allele.

MTHFR catalyzes the conversion of folate into its active form, which is essential for the methylation cycle that produces countless regulatory molecules, including nitric oxide. Nitric oxide is a critical player in vascular tone and pain modulation; it regulates blood flow and influences how pain signals are transmitted in the nervous system. MTHFR also affects homocysteine metabolism; impaired MTHFR function allows homocysteine to accumulate, which increases inflammation and pain sensitivity.

The MTHFR C677T variant, present in roughly 40% of people of European ancestry, reduces enzyme efficiency by 35 to 70%. The C677T variant impairs nitric oxide production and allows homocysteine to rise, both of which increase pain sensitivity and worsen chronic pain and migraine severity. This is one of the strongest genetic risk factors for migraine with aura, but it also affects baseline pain sensitivity across the board.

If you carry the MTHFR C677T variant, you may notice that your pain worsens during periods of high stress, poor sleep, or when you’re not eating enough folate-rich foods. You might have a family history of migraines or chronic pain. Your pain may feel worse in the morning, especially if you’re not sleeping well, because impaired methylation during sleep-deprived states drops nitric oxide further. Cold temperatures may worsen your pain because reduced nitric oxide impairs vasodilation.

BDNF is a growth factor that supports the survival and function of neurons, particularly in pain-processing circuits. In chronic pain conditions, BDNF levels become abnormally high in pain-processing regions of the spinal cord and brain, which causes pain sensitivity to escalate. BDNF drives a process called central sensitization, where the nervous system becomes hyper-responsive to pain signals, amplifying minor inputs into major pain experiences. This is why people with chronic pain often find their pain spreading or intensifying over time.

The BDNF Val66Met variant, carried by roughly 30% of people, is associated with altered pain response and increased fibromyalgia risk. Met-allele carriers show heightened central sensitization, meaning their nervous systems more readily amplify pain signals and develop persistent pain states. This variant doesn’t cause pain directly; it affects how readily your nervous system enters central sensitization, the state where pain becomes self-perpetuating.

If you carry the BDNF Met allele, you may notice that your pain spreads to new areas over time, that emotional stress dramatically worsens your pain, or that you develop widespread pain patterns (fibromyalgia-like symptoms). Your pain may feel like it’s in the nervous system rather than localized to a joint or muscle. You may be hypersensitive to touch, temperature changes, and pressure. Recovery from minor injuries takes longer because your nervous system struggles to return to baseline sensitivity.

GCH1 encodes GTP cyclohydrolase 1, an enzyme that synthesizes tetrahydrobiopterin (BH4), a critical cofactor for the production of several pain-relief neurotransmitters: dopamine, serotonin, and nitric oxide. Without adequate BH4, your cells cannot efficiently produce these protective neurochemicals. BH4 is also essential for immune regulation; low BH4 allows inflammation to amplify pain signals. Think of GCH1 as the gatekeeper to pain-relief production; if GCH1 activity is low, pain-modulating neurotransmitter synthesis stalls.

GCH1 variants, present in roughly 15 to 20% of the population, reduce enzyme activity and thus BH4 availability. People with GCH1 variants have lower capacity to produce pain-modulating neurotransmitters and are more susceptible to pain sensitization, particularly in high-stress contexts where BH4 demand increases. Stress depletes BH4 rapidly, so variant carriers may notice dramatic pain flares during stressful periods.

If you carry a GCH1 variant, you likely experience stress-induced pain flares, worsening of chronic pain during psychological stress, and difficulty recovering pain sensation to baseline after stress. You may find that your pain is highly mood-dependent and that depression or anxiety precedes pain escalation. Your pain may worsen in the winter or during seasons of high stress, when BH4 demand is highest and supply is lowest.

FAAH encodes fatty acid amide hydrolase, an enzyme that breaks down anandamide, an endocannabinoid that your body produces naturally. Anandamide is sometimes called the endogenous equivalent of THC; it binds to cannabinoid receptors and suppresses pain signals, reduces inflammation, and promotes emotional regulation. FAAH determines how long anandamide persists in your nervous system. Higher FAAH activity means anandamide is cleared quickly, reducing pain relief duration. Lower FAAH activity means anandamide lingers, providing more sustained pain suppression.

The FAAH C385A variant (rs324420), with the A allele present in roughly 20 to 30% of the population, reduces FAAH enzyme activity. A-allele carriers have elevated anandamide levels, which provides enhanced natural pain relief, reduced inflammation, and lower pain sensitivity compared to C-allele homozygotes. This is one of the few genetic variants that is genuinely protective for chronic pain.

If you carry the FAAH A allele, you may notice that you recover faster from pain, tolerate exercise better, and have a naturally higher pain threshold. You may respond well to endocannabinoid-supporting interventions. If you don’t carry the A allele (meaning you’re C/C), you have lower baseline anandamide and may find that pain interventions focused on endocannabinoid enhancement (exercise, certain foods, stress reduction) work especially well for you.